Open an account

Jupiter Neurosciences

JUNS · NASDAQ

$2.80+$0.05 (+1.82%)TodayMarket closed ·
Prev close $2.75

About JUNS

Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The company is headquartered in Palm Beach Gardens, Florida and currently employs 5 full-time employees. The company went IPO on 2024-12-03. The firm has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The firm has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. The company has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.

Employees
5
Headquarters
Palm Beach Gardens, Florida
Listed
Dec 3, 2024
Sector
Health Care
Industry
Pharmaceuticals
Website
jupiterneurosciences.com

JUNS key statistics

Market cap
3.69M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
93.40K
Volume
11.23K
Open price
$2.75
High today
$3.24
Low today
$2.75
52 Week high
$11.20
52 Week low
$2.25

Jupiter Neurosciences (JUNS) at a glance

As of Oct 20, 2026, Jupiter Neurosciences (JUNS) shares are priced at $2.80, giving the company a market cap of 3.69M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.75 and $3.24. The current price is 1.8% above the day's low and 13.6% below its high.

Volume so far is 11.23K shares, below the average of 93.40K shares a day.

Over the past year Jupiter Neurosciences has ranged from $2.25 to $11.20, and now sits 6% of the way up that range.

Jupiter Neurosciences met or beat analyst EPS estimates in 3 of the last 5 quarters. In Q4 FY25 it reported -$5.03 per share against an estimate of -$5.36.

JUNS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 5 quarters, by 7.4% on average.

  1. Q4 FY24: reported -$3.75 per share against an estimate of -$1.53
  2. Q1 FY25: reported -$3.75 per share against an estimate of -$2.30
  3. Q2 FY25: reported -$5.25 per share against an estimate of -$5.36
  4. Q3 FY25: reported -$5.25 per share against an estimate of -$6.12
  5. Q4 FY25: reported -$5.03 per share against an estimate of -$5.36

JUNS news

  • Avi Kapoor

    Dow Falls Over 300 Points; SAIC Shares Jump After Upbeat Q2 Results

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Avi Kapoor

    Dow Jumps 350 Points; BJ's Wholesale Club Posts Upbeat Earnings

  • Henry Khederian

    Jupiter Neurosciences Stock Surges Friday: What's Driving the Action?

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Press releaseGlobe Newswire

    PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

Similar companies

Companies in the same industry as Jupiter Neurosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.